BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19138962)

  • 41. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
    Mei FC; Young TW; Liu J; Cheng X
    FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy.
    Brueckner B; Lyko F
    Trends Pharmacol Sci; 2004 Nov; 25(11):551-4. PubMed ID: 15491775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA methylation biomarkers in cancer: progress towards clinical implementation.
    Mikeska T; Bock C; Do H; Dobrovic A
    Expert Rev Mol Diagn; 2012 Jun; 12(5):473-87. PubMed ID: 22702364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
    Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
    Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Global epigenetic profiling in bladder cancer.
    Dudziec E; Goepel JR; Catto JW
    Epigenomics; 2011 Feb; 3(1):35-45. PubMed ID: 22126151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decitabine--bedside to bench.
    Oki Y; Aoki E; Issa JP
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
    Belinsky SA; Klinge DM; Stidley CA; Issa JP; Herman JG; March TH; Baylin SB
    Cancer Res; 2003 Nov; 63(21):7089-93. PubMed ID: 14612500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methylation and liver cancer.
    Raggi C; Invernizzi P
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):564-71. PubMed ID: 23806627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation inhibitors in cancer: recent and future approaches.
    Gros C; Fahy J; Halby L; Dufau I; Erdmann A; Gregoire JM; Ausseil F; Vispé S; Arimondo PB
    Biochimie; 2012 Nov; 94(11):2280-96. PubMed ID: 22967704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA Methyltransferase Inhibitors: Development and Applications.
    Lopez M; Halby L; Arimondo PB
    Adv Exp Med Biol; 2016; 945():431-473. PubMed ID: 27826847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Roles of DNA Methylation in the Stages of Cancer.
    McMahon KW; Karunasena E; Ahuja N
    Cancer J; 2017; 23(5):257-261. PubMed ID: 28926425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective.
    Gherardini L; Sharma A; Capobianco E; Cinti C
    Curr Pharm Biotechnol; 2016; 17(10):856-65. PubMed ID: 27229488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics.
    Zelent A; Petrie K; Boix-Chornet M; Melnick AM; Waxman S; Gore SD
    Cancer Res; 2008 Jul; 68(13):4967-70. PubMed ID: 18593891
    [No Abstract]   [Full Text] [Related]  

  • 55. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
    Moreaux J; Bruyer A; Veyrune JL; Goldschmidt H; Hose D; Klein B
    Br J Haematol; 2014 Feb; 164(4):613-6. PubMed ID: 24224771
    [No Abstract]   [Full Text] [Related]  

  • 56. Antimutagenesis/anticarcinogenesis 2001: mechanistic studies.
    Gentile JM; Gentile G; Lohman PH; Ferguson LR
    Mutat Res; 2001 Sep; 480-481():1-7. PubMed ID: 11506794
    [No Abstract]   [Full Text] [Related]  

  • 57. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets.
    Hong WK; Spitz MR; Lippman SM
    J Clin Oncol; 2000 Nov; 18(21 Suppl):9S-18S. PubMed ID: 11060320
    [No Abstract]   [Full Text] [Related]  

  • 58. Epigenetics.
    Issa JP; Just W
    FEBS Lett; 2011 Jul; 585(13):1993. PubMed ID: 21693122
    [No Abstract]   [Full Text] [Related]  

  • 59. A Nexus model of cellular transition in cancer.
    Yadav M; Chatterjee P; Tolani S; Kulkarni J; Mulye M; Chauhan N; Sakhi A; Gorey S
    Biol Res; 2018 Aug; 51(1):23. PubMed ID: 30086794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conservation and divergence in eukaryotic DNA methylation.
    Lee TF; Zhai J; Meyers BC
    Proc Natl Acad Sci U S A; 2010 May; 107(20):9027-8. PubMed ID: 20457928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.